Five hundred seventy CD-1 mice were divided equally by gender and assigned to three groups of 70 per gender and one group of 75 per gender. The first three groups were dosed via oral intubation at 0, 0.5, and 2.0 mg/kg/day while the larger groups were dosed at 4.5 mg/kg/day. Observations were made twice daily and blood smears taken at 12 and 18 months. All animals were sacrificed at 18 months; organs were weighed and examined grossly and microscopically. Treated animals showed decreased body weight gain and male mice demonstrated increased mortality, particularly at the high-dose level. Gross and microscopic lesions were not obviously dose dependent. In this study, acrolein was not shown to have oncogenic properties.
References
1.
1. Draminski, W., Eder, E. and Henschler, D. (1983). Anew pathway of acrolein metabolism in rats. Arch. Toxicol.52(3), 243–247.
2.
2. Esterbauer, H., Ertl, A., and Scholz, N. (1976). The reaction of cysteine with α, β-unsaturated aldehydes. Tetrahedron32, 285–289.
3.
3. Wilmer, J.L., Erexson, G.L., and Kligerman, A.D. (1988). Aberration of cytogenetic damage by 2-mercaptoet-hane sulfonate in cultured human lymphocytes exposed to cyclophosphamide and its reactive metabolites. Cancer Res.46, 203–210.
4.
4. Beauchamp Jr., R.O., Andjelkovich, D.A., Kligerman, A.D., Morgan, K.T., and Heck, H.D. (1985). A critical review of the literature on acrolein toxicity, CRC Crit. Rev. Toxicol.14(4), 309–380.
5.
5. Hemmininki, K., Falck, K. and Vainio, H. (1980). Comparison of alkylation rates and mutagenicity of directly acting industrial and laboratory chemicals. Arch. Toxicol.46, 277–285.
6.
6. U.S.E.P.A., Health Assessment Document for Acrolein. (1986). EPA/600/8–86–014A, PB87–139960, pp. 1–1–8–5, September, Washington, DC.
7.
7. Weber-Tschopp, A., Fisher, T., Gierer, F., and Grandjean, E. (1977). Experimentally induced irritating effects of acrolein on men. Int. Arch. Occup. Environ. Health40(2), 117–130.
8.
8. Catilina, P., Champeix, J., and Andraud, G. (1970). Expérimentation Des Toxiques Pulmonaires: L'example De L'acroléine. Poumon Coeur26(8), 867–876.
9.
9. Gosselin, B., Wattle, F., Chopin, C., Degand, P., Fruchart, J.C., Van Der Loo, D., and Crasquin, O. (1979). Intoxication Aiguë Par L'acroléine. Nouv. Presse Med.8(30), 2469–2472.
10.
10. Nielsen, G.D., Bakbo, J.C., and Holst, E. (1984). Sensory initiation and pulmonary irritation by allyl acetate, allyl alcohol and allyl ether compared to acrolein. Acta. Pharmacol. Toxicol.54(4), 292–298.
11.
11. Schiffmann, D., Eder, E., Neudecker, T., and Henschler, D. (1983). Induction of unscheduled DNA synthesis in He La cells by allylic compounds. Cancer Letters20, 263–269.
12.
12. Izard, M.C. (1973). Recherches sur les Effects Mutagènes de l'acroléine et de ses Deux Époxydes: Le Glycol Et Le Glycidal, Sur Saccharomyces cerevisiae. C. R. Acad. Sc. Paris276, 3037–3040.
13.
13. Hales, B.F. (1982). Comparison of mutagenicity and teratogenicity of cyclophosphamide and its metabolites, 4-hydroxycyclophosphamide, phosphamide mustard and acrolein. Cancer Res.42(8), 3016–3021.
14.
14. Au, W., Sokova, O.I., Kopnin, B., and Arrighi, F.E. (1980). Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro. Cytogenet. Cell Genet.26, 108–116.
15.
15. Marnett, L.J., Hurd, H.K., Hollstein, M.C., Levin, D.E., Esterbauer, H., and Ames, B.N. (1985). Naturally occurring carbonyl compounds are mutagens in Salmonella tester strain TA 104. Mutat. Res.148, 25–34.
16.
16. Lutz, D., Eder, E., Neudecker, T., and Henschler, D. (1982). Structure-mutagenicity relationship in α,β-unsaturated carbonylic compounds and their corresponding allylic alcohols. Mutat. Res.93, 305–315.
17.
17. Hayworth, S., Lawlor, T., Mortelmans, K., Speck, W., and Zeiger, E. (1983). Salmonella mutagenicity test results for 250 chemicals. Environ. Mutagen. Suppl.1, 3–142.
18.
18. Luinsky, W. and Andrews, A.W. (1980). Mutagenicity of vinyl compounds in Salmonella typhimurium. Terat. Carc. Mut.1, 259–267.
19.
19. Parent, R.A. and Caravello, H.E. Unpublished results.
20.
20. Luinsky, W.L. and Reuber, M.D. (1987). Chronic carcinogenesis studies of acrolein and related compounds. Toxicol. Inc. Health3(3), 337–345.
21.
21. Luinsky, W.L. (1988). Chronic studies in rodents of vinyl acetate and compounds related to acrolein. Ann. N. Y. Acad. Sci.534, 246–254.
22.
22. Feron, V.J. and Kruysse, A. (1977). Effects of exposure to acrolein vapor in hamsters simultaneously treated with benzo[a]pyrene or diethylnitrosamine. J. Toxicol. Environ. Health3, 379–394.
24. Salaman, M.H. and Roe, F.J.C. (1956). Further tests for tumor-initiating activity. N,N-di-(2-chloroethyl)-p-aminophenyl butyric acid (CB 1348) as an initiator of skin tumor formation in the mouse. Br. J. Cancer10, 363–378.
25.
25. Steiner, P.E., Steele, R., and Koch, F.C. (1943). The possible carcinogenicity of overcooked meats, heated cholesterol, acrolein and heated sesame oil. Cancer Res.3, 100–107.
26.
26. Parent, R.A., Caravello, H.E., and Long, J.E. (1992). Two year toxicity and carcinogenicity study of acrolein in rats. J. Appl. Toxicol.11.
27.
27. Cox, D. and Oakes, D. (1984). Analysis of Survival Data. New York: Chapman and Hall.
28.
28. Haseman, J. (1984). Statistical issues in the design, analysis, and interpretation of animal carcinogenicity studies. Environ. Health Perspect.58, 385–392.
29.
29. Kalbfleisch, J. and Prentice, R. (1980). The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, Inc.
30.
30. SAS. (1990). SAS/STAT User's Guide. Volume 2, GLM-Varcomp. Version 6. Fourth Edition. SAS Institute, Inc., Cary, NC.
31.
31. Rao, G.N., Birnbaum, L.S., Collins, J.J., Tennant, R.W., and Skow, L.C. (1984). Mouse strains for chemical carcinogenicity studies: Overview of a workshop. Fund. Appl. Toxicol.10, 385–394.
32.
32. Homburger, F., Russfield, A.B., Weisburger, J.H., Lim, S., Chak, S.P., and Weisburger, E.K. (1975). Aging changes in CD-1 HaM/ICR mice reared under standard laboratory conditions. J. Natl. Cancer Inst.55(1), 37–45.
33.
33. Grasso, P., Crampton, R.F., and Hooson, J. (1977). The mouse and carcinogenicity testing. Surrey, England: The British Industrial Biological Research Association, 197 pp.
34.
34. Lang, P.L. (1987). Spontaneous Neoplastic Lesions in the Crl:CD-1® [ICR]BR Mouse. Wilmington, MA: Charles River, 13 pp.
35.
36. Bowmer, K.H. and Higgins, M.L. (1976). Some aspects of the persistence and fate of acrolein in water. Arch. Environ. Contam. Toxicol.5, 87–96.
36.
37. Curren, R.D., Yang, L.L., Conklin, P.M., Grafstrom, R.C., and Harris, C.C. (1988). Mutagenesis of xeroderma pigmentosum fibroblasts by acrolein. Mutat. Res.209, 17–22.
37.
38. Izard, C. and Liberman, C. (1978). Acrolein. Mutat. Res.47, 115–138.
38.
39. Crook, T.R., Souhami, R.L., and Mclean, A.E.M. (1986). Cytotoxicity, DNA cross-linking and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res.46(10), 5029–5034.
39.
40. Cox, R., Goorha, S., and Irving, C.C. (1988). Inhibition of DNA methylase activity by acrolein. Carcinogenesis9(3), 463–465.
40.
41. Foiles, P.G., Akerkar, S.A., and Chung, F.L. (1989). Application of an immunoassay for cyclic acrolein deoxyguanosine adducts to assess their formation in DNA of Salmonella typhimurium under conditions of mutation induction by acrolein. Carcinogenesis10(1), 87–90.
41.
42. Munsch, N., De Recondo, A.M., and Frayssinet, C. (1973). Effects of acrolein on DNA synthesis in vitro. Fed. Eur. Biochem. Soc. Lett.30(3), 286–290.
42.
43. Parent, R.A., Caravello, H.E., and Harbell, J.W. (1991). Gene mutation assay of acrolein in the CHO/HGPRT test system. J. Appl. Toxicol.11(2), 91–95.
43.
44. Parent, R.A., Caravello, H.E., and Hoberman, A.M. (1992). Reproductive effects of acrolein on two generations of rats. Fund. Appl. Toxicol. Accepted for Publication.
44.
45. Parent, R.A. and Caravello, H.E. (1990). On the toxicity and carcinogenicity of acrolein. Abstracts of Annual meeting of the European Societies of Toxicology (EUROTOX 1990), Leipzig, DDR, September 12–14, 1990, p. 167.
